Jci_page_head_homepage_01 Jci_page_head_homepage_02
Sohvi Hörkkö, David A. Bird, Elizabeth Miller, Hiroyuki Itabe, Norbert Leitinger, Ganesamoorthy Subbanagounder, Judith A. Berliner, Peter Friedman, Edward A. Dennis, Linda K. Curtiss, Wulf Palinski, Joseph L. Witztum
Published in Volume 103, Issue 1
J Clin Invest. 1999; 103(1):117–128 doi:10.1172/JCI4533
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 1

(a) Immunoassay showing binding of natural monoclonal autoantibodies from apoE-deficient mice (EO1–EO17), a murine MAB from mice immunized with homogenates of human atheromatous plaque (DLH3) and MDA2 (a murine MAB to MDA-lysine), to BSA, native LDL, LDL oxidized with copper for 16 h (CuOx-LDL), and MDA-modified LDL (MDA-LDL). The antigens were plated at 10 μg/ml overnight (4°C), and the purified antibodies were incubated with antigen at 10 μg/ml for 1 h (room temperature). The amount of antibody bound was then measured with alkaline phosphatase–labeled goat anti–mouse IgM (or anti-IgG for MDA2) antibody using chemiluminescent technique. Each bar is the mean of triplicate determinations. (b) Competition immunoassay showing binding of a fixed and limiting dilution of biotinylated EO6 MAB to immobilized CuOx-LDL in the presence of increasing amounts of nonimmune mouse IgM, EO6, and MAB DLH3. LDL, low-density lipoproteins; MAB, monoclonal antibody; MDA, malondialdehyde; RLU, relative light units.